Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

MMWR: Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors

This guideline presents updated data about drug interactions between protease inhibitors and non-nucleoside reverse transcriptase inhibitors for treatment of HIV infection together with rifamycins for treatment of TB.

Author:

Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR

Topic:

Case Management, Treatment Guidelines Materials, HIV Co-infection, Treatment- TB Disease, TB Treatment, Treatment- Medication Information

Country of Origin:

United States

View Webpage

Related Materials

MMWR: Clinical Update: Impact of HIV Protease Inhibitors on the Treatment of HIV - Infected Tuberculosis Patients With Rifampin

This report describes approaches for managing patients with TB who are candidates for or who are undergoing protease inhibitor therapy and presents interim recommendations for managing these patients until additional data are available and formal guidelines are issued. Protease inhibitors interact with rifamycin derivatives, which are used to treat and prevent the mycobacterial infections commonly observed in patients with the HIV. The report provides background information on the management of TB and the three treatment options currently available for these patients. The concurrent use of protease inhibitors with rifampin might be possible by modifying the doses of both to compensate for the drug interaction.

Report

Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care (2017 update)

These guidelines contain policy recommendations on priority areas in the treatment of drug-susceptible TB and patient care.

Guideline

WHO guidelines on tuberculosis infection prevention and control: 2019 update

The revised guidelines includes recommendations for specific administrative controls, environmental controls, and respiratory protection controls.

Guideline

Global resources for the prevention,
management, and elimination of TB.